Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,638 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: One MORE Clear all

Conditions: Breast Cancer
Interventions: 99m Tc-TM; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endograft Implantation to Repair Abdominal Aortic Aneurysm
Interventions: Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM); Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atrial Flutter, Ventricular Tachycardia
Interventions: Amigo catheter robot; Device
Lead sponsor: Catheter Robotics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Newport Beach, California • Redwood City, California • Chicago, Illinois + 8 more

Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions: Encorafenib Pill, Binimetinib Pill, Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria
Interventions: Hemin for injection, Placebo; Biological · Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Age Related Macular Degeneration
Interventions: ranibizumab, dexamethasone and verteporfin, Ranibizumab; Drug
Lead sponsor: Bay Area Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more

Conditions: Muscular Dystrophy, Facioscapulohumeral
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Palo Alto, California • Iowa City, Iowa • Kansas City, Kansas + 3 more

Conditions: Alzheimer's Disease (AD)
Interventions: [18F]T807; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 20 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Allogeneic HCT, Consolidation chemotherapy; Procedure · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions: Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy; Other · Genetic · Drug
Lead sponsor: University of Washington; Other
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis, Skin Ulcer, Leg Ulcer, Pyoderma, Peripheral Arterial Disease, Lymphedema, Surgical Complication, Venous Leg Ulcers (VLUs), Calciphylaxis, Sickle Cell Ulcer, Pressure Ulcer (PU), Diabetic Foot Ulcers (DFUs), Pressure Injury, Arterial Ulcers, Soft Tissue Radionecrosis (STRN), Traumatic Wounds, Chronic Ulcer
Interventions: Usual care; Other
Lead sponsor: U.S. Wound Registry; Other
Eligibility: Not listed
Enrollment: 300,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2030
U.S. locations: 1
States / cities: The Woodlands, Texas

Conditions: Traumatic Brain Injury
Interventions: MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval, Blocked Retrieval; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Renal Cell Carcinoma Stage IV
Interventions: mHealth Smart Phone Application, eHEALS digital literacy test, Weekly Quiz, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Patient Post Intervention Survey; Other · Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Solid Tumor
Interventions: NB003 tablets; Drug
Lead sponsor: Ningbo Newbay Technology Development Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Stanford, California • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Glaucoma
Interventions: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Drug Interactions, Neoplasms
Interventions: GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease
Interventions: Naltrexone, Placebo, sugar pill; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Migraine
Interventions: Treximet, Placebo; Drug
Lead sponsor: Premiere Research Institute; Other
Eligibility: 12 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more

Conditions: Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions: 80 mg RPH-104, Placebo; Biological · Drug
Lead sponsor: R-Pharm Overseas, Inc.; Industry
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more

Conditions: Small Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions: RO7616789, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Detroit, Michigan + 7 more

Conditions: Breast Cancer, Cognitive Change, Cognitive Impairment, Quality of Life
Interventions: Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, Road Tour, Computerized Crossword Puzzles; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Alcohol Drinking
Interventions: Naltrexone; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Undiagnosed Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland

Search by objective public record fields.

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair

Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Panhematin for Prevention of Acute Attacks of Porphyria

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Leukemia Stem Cell Detection in Acute Myeloid Leukemia

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

A Real-World Registry of Chronic Wounds and Ulcers

Pilot and Feasibility of MEMI for Chronic Traumatic Brain Injury

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

A Study of NB003 in Patients With Advanced Malignancies

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Circadian Ocular Perfusion Pressure and Ocular Blood Flow

A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

Treximet Early Intervention Adolescent Migraine

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Computerized Cognitive Training in Breast Cancer Survivors

Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

Adult Patients With Undiagnosed Conditions and Their Responses to Clinically Uncertain Results From Exome Sequencing